Literature DB >> 6957974

Spirometric studies in non-smoking, healthy adults.

A A Viljanen, P K Halttunen, K E Kreus, B C Viljanen.   

Abstract

Reference spirometric values for vital capacity (VC), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), forced expiratory volume in one second as percentage of vital capacity or of forced vital capacity (FEV%), the highest flow during forced inspiration (Vmax insp), the highest forced expiratory flow at 50% vital capacity (Vmax 50%), the highest forced expiratory flow when 75% of vital capacity has been expired (Vmax 25%), Vmax insp/Vmax 50% and peak expiratory flow (PEF) were determined in a series of 296 males and 257 females, 18-65 years old, who have never smoked. Equations were derived using height and age as predictors. The reproducibility was tested.

Mesh:

Year:  1982        PMID: 6957974

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  49 in total

1.  Environmental tobacco smoke and adult-onset asthma: a population-based incident case-control study.

Authors:  Maritta S Jaakkola; Ritva Piipari; Niina Jaakkola; Jouni J K Jaakkola
Journal:  Am J Public Health       Date:  2003-12       Impact factor: 9.308

2.  Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study.

Authors:  Tuula Toljamo; Marjo Kaukonen; Pentti Nieminen; Vuokko L Kinnula
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

Review 3.  Spirometry.

Authors:  Theodore G Liou; Richard E Kanner
Journal:  Clin Rev Allergy Immunol       Date:  2009-04-04       Impact factor: 8.667

4.  Influence of subclinical hypothyroidism and T4 treatment on the prevalence and severity of obstructive sleep apnoea syndrome (OSAS).

Authors:  O Resta; P Carratù; G E Carpagnano; M Maniscalco; G Di Gioia; D Lacedonia; R Giorgino; G De Pergola
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

5.  Long-term CPAP treatment improves asthma control in patients with asthma and obstructive sleep apnoea.

Authors:  Paula Kauppi; Patrick Bachour; Paula Maasilta; Adel Bachour
Journal:  Sleep Breath       Date:  2016-04-07       Impact factor: 2.816

6.  Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma.

Authors:  O Selroos; A B Löfroos; A Pietinalho; H Riska
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

7.  Measuring the bronchial effect of bronchodilating drugs in healthy subjects after methacholine provocation. Salbutamol as a model drug.

Authors:  O P Seppälä; E Iisalo
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study.

Authors:  Noora Louhelainen; Harri Stark; Witold Mazur; Paula Rytilä; Ratko Djukanovic; Vuokko L Kinnula
Journal:  BMC Pulm Med       Date:  2010-03-14       Impact factor: 3.317

9.  Lung function and nervous system involvement in asbestosis.

Authors:  O Korhonen; J Juntunen; M Huuskonen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1983

10.  Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment.

Authors:  A R A Sovijärvi; T Haahtela; H J Ekroos; A Lindqvist; A Saarinen; T Poussa; L A Laitinen
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.